Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 erdafitinib versus chemotherapy or pembrolizumab in advanced urothelial cancer with FGFR aberrations
2017-002932-18Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and Renal pelvis urothelial carcinoma (UTUC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)Renal pelvis urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2017-002932-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002932-18.